# Safety and Efficacy of Talampanel in Glioblastoma Multiforme

> **NCT00267592** · PHASE2 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 72 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** Talampanel
- **RADIATION:** Radiation Therapy (RT) 5 days a week +
- **DRUG:** temozolomide(TMZ) 75mg
- **DRUG:** adjuvant TMZ 200mg

## Key facts

- **NCT ID:** NCT00267592
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2008-09
- **Final completion:** 2011-02
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2016-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00267592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00267592, "Safety and Efficacy of Talampanel in Glioblastoma Multiforme". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00267592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*